Dr. Sordillo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
51 East 82nd Street
New York, NY 10028Phone+1 917-922-9540
Summary
- Peter P. Sordillo, M.D., PhD is an oncologist in New York, NY, affiliated with Lenox Hill Hospital. He is also Vice-President and Chief Scientific and Medical Officer at SignPath Pharma, a biotechnology firm: and Research Consultant, Institute for Ultrafast Spectroscopy and Lasers, Physics Department, City University of New York.
Clinical Expertise
- Glioblastoma, Pancreatic cancer, Colon cancer, Medical Oncology and Hematology, Optics and Photonics, Causality and Metaphysics, Quantum Physics and Quantum Computing, Soft-tissue Sarcoma
Education & Training
- New York UniversityMS, Physics, 1991 - 2001
- Columbia University Graduate School of Arts and SciencesPhD, Philosophy (Quantum Mechanics and Causality), 1982 - 1990
- Columbia UniversityMPhil, Philosophy, 1980 - 1982
- Columbia UniversityM.A., Philosophy, 1978 - 1980
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1977 - 1980
- Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1974 - 1977
- New York Medical CollegeClass of 1974
- Columbia College AB, major - Philosophy; minor - Biochemistry (Pre- Medical), English Literature, 1966 - 1970
Certifications & Licensure
- NY State Medical License 1975 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Fellow American College of Physicians, 1984
- Junior Faculty Clinical Award American Cancer Society, 1982-1984
- Basic Science Research Award, "The Effects of Chemotherapy on Tumor Cell Growth in the Nude Mouse" Memorial Sloan-Kettering Cancer Center, 1979
- Join now to see all
Clinical Trials
- Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas Start of enrollment: 2023 Mar 03
Publications & Presentations
PubMed
- 3 citationsSuppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma.Laura A Sordillo, Peter P Sordillo
Anticancer Research. 2023-12-01 - The complex lipid, SPPCT-800, reduces lung damage, improves pulmonary function and decreases pro-inflammatory cytokines in the murine LPS-induced acute respiratory dis...Peter P Sordillo, Andrea Allaire, Annie Bouchard, Dan Salvail, Sebastien M Labbe
Pharmaceutical Biology. 2022-12-01 - 8 citationsRelationship between the in vitro efficacy, pharmacokinetics and in vivo efficacy of curcumin.Gordon T Bolger, Kresimir Pucaj, Yvonne O Minta, Peter Sordillo
Biochemical Pharmacology. 2022-11-01
Journal Articles
- A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc�) in patients with locally advanced or metastatic cancerGreil, R., Greil-Ressler, S., Weiss, L., Sch�nlieb, C., Magnes, T., Radl, B., Bolger, G.T., Vcelar, B. and Sordillo, P.P., Cancer chemotherapy and pharmacology, 1/1/2018
- Distribution of curcumin and THC in peripheral blood mononuclear cells isolated from healthy individuals and patients with chronic lymphocytic leukemiaBolger, G.T., Licollari, A., Tan, A., Greil, R., Pleyer, L., Vcelar, B., Majeed, M. and Sordillo, P.P., Anticancer research, 1/1/2018
- Pharmacokinetics of liposomal curcumin (Lipocurc�) infusion: effect of co-medication in cancer patients and comparison with healthy individualsBolger, G.T., Licollari, A., Tan, A., Greil, R., Vcelar, B., Greil-Ressler, S., Weiss, L., Sch�nlieb, C., Magnes, T., Radl, B., Majeed, M. and Sordillo, P.P., Cancer chemotherapy and pharmacology, 1/1/2018
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Alzheimer�s disease: label-free fluorescence shows increases in indoleamine 2,3-dioxygenase (IDO) activity in affected areas of the brain.Sordillo, L.A., Zhang, L., Shi, L., Sordillo, P.P. and Alfano, R.R., Optical Biopsy XVII: Toward Real-Time Spectroscopic Imaging and Diagnosis; International Society for Optics and Photonics, 1/1/2019
- Advances in medical applications using SWIR light in the wavelength range from 1600 to 2350 nm.Sordillo, L.A., Zhang, L., Shi, L., Sordillo, P.P. and Alfano, R.R., Optical Biopsy XVII: Toward Real-Time Spectroscopic Imaging and Diagnosis; International Society for Optics and Photonics, 1/1/2019
- Optical fluorescence to assess abnormal tryptophan metabolic activity in brain samples from Alzheimer�s patients.Sordillo, L.A., Zhang, L., Shi, L., Sriramoju, V., Sordillo, P.P. and Alfano, R.R., CLEO: Applications and Technology; Optical Society of America, 1/1/2018
- Join now to see all
Press Mentions
- SignPath Pharma Reports Extremely Beneficial Blood Level Results of Its Phase 1b Clinical Trials of Liposomal Curcumin in Advanced Cancer Patients as Published in the Cancer Research Journal “Cancer Chemotherapy and Pharmacology”October 24th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: